Seminars in Oncology
Volume 30, Issue 3 , Pages 401-412 , June 2003

The follow-up of ovarian cancer

  • Ami P. Vaidya

      Affiliations

    • Department of Obstetrics and Gynecology, New York University Medical Center, New York, NY, USA
    • ,
  • John P. Curtin

      Affiliations

    • *Address reprint requests to John P. Curtin, MD, Director Gynecologic Oncology, 550 First Ave, Suite 9R, New York, NY 10016 USA
    • Department of Obstetrics and Gynecology, New York University Medical Center, New York, NY, USA

References 

  1. McGuire W, Hoskins J, Brady FB, et al.  Cyclophosphimide and cisplatin compared with paclitaxel and cisplatin in patients with stage II and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  2. Barnhill D, O’Connor D, Farley J, et al.  Clinical surveillance of gynecologic cancer patients. Gynecol Oncol. 1992;46:275–280
  3. Easton DR, Bishop DT, Ford D, et al.  Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet. 1993;52:678–701
  4. Bellacosa A, Genuardi M, Anti M, et al.  Hereditary nonpolyposis colorectal cancer: Review of clinical, molecular genetics, and counseling aspects. Am J Med Genet. 1996;24:353–364
  5. Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535–1538
  6. Bast RC, Feeny M, Lazarus H, et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–1337
  7. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–245
  8. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol. 1992;44:207–212
  9. Crombach G, Zippel HH, Wurz H. Clinical significance of cancer antigen 125 in ovarian cancer. Cancer Detect Prev. 1985;8:135–139
  10. Rustin GJ, Marples M, Nelstrop AE, et al.  Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054–4057
  11. Benedetti PP, Scamba G, Baiocchi G, et al.  Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer. Gynecol Oncol. 1989;35:286–289
  12. Rubin S, Hoskins W, Hakes T, et al.  Serum CA-125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989;160:667–671
  13. Rustin GJ, Nelstrop AE, Tuxen MK, et al.  Defining progression of ovarian cancinoma during follow-up according to CA125: A North Thames Ovary Group study. Ann Oncol. 1996;7:336–361
  14. Friedman JB, Weiss NS. Second thoughts about second-look laparotomy in advanced ovarian cancer. N Engl J Med. 1990;322:1079–1082
  15. DeRosa V, Mangoni di Stefano M, Brunetti A, et al.  Computed tomography and second-look surgery in ovarian cancer patients: Correlation, actual role and limitations of CT scan. Eur J Gynecol Oncol. 1995;16:123–129
  16. Pectasides D, Kayianni H, Facou A, et al.  Correlation of abdominal computed tomography scanning and second-look operation findings in ovarian cancer patients. Am J Clin Oncol. 1991;14:457–462
  17. Calkins A, Stehman F, Wass J, et al.  Pitfalls in interpretation of computed tomography prior to second-look laparotomy in patients with ovarian cancer. Br J Radiol. 1987;60:975–979
  18. Lund B, Jacobsen K, Rasch L, et al.  Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma. Gynecol Oncol. 1990;37:279–283
  19. Murolo C, Costantini S, Foglia G, et al.  Ultrasound examination in ovarian cancer patients: A comparison with second-look laparotomy. J Ultrasound Med. 1989;8:441–443
  20. Prayer L, Kainz C, Kramer J, et al.  CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr. 1993;17:626–632
  21. Low R, Saleh F, Song S, et al.  Treated ovarian cancer: Comparison of MR imaging with serum CA-125 level and physical examination—A longitudinal study. Radiology. 1999;221:519–528
  22. Podratz K, Malkasian G, Wiend H, et al.  Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol. 1988;29:274–282
  23. Casey M, Gupta N, Muths C. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol. 1993;53:331–338
  24. Zimny M, Siggelkow W, Schroder W, et al.  2-[Flourine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2001;83:310–315
  25. Nakamoto Y, Saga T, Ishimori T, et al.  Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. Am J Roentgenol. 2001;176:1449–1454
  26. Cho SM, Ha HK, Byun JY, et al.  Usefulness of FDG PET for the assessment of early recurrent epithelial ovarian cancer. Am J Roentgenol. 2002;179:391–395
  27. Randall TC, Rubin SC. Second look laparotomy. In Ovarian Cancer. In:  eds Rubin SC,  Sutton GP editor. Philadelphia, PA: Lippincott,; 2001;p. 273–284
  28. Rubin SC, Randall TC, Armstrong KA, et al.  Ten Year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999;93:21–24
  29. Rubin SC, Jones WB, Curtin JP, et al.  Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol. 1993;82:139–142
  30. Cacciari N, Zamagni C, Strocchi E, et al.  Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: Retrospective analysis of the role of second-look. Eur J Gynecol Oncol. 1999;20:56–60
  31. Husain A, Chi DS, Prasad M, et al.  The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol. 2000;80:44–47
  32. Clough KB, Ladonne JM, Nos C, et al.  Second look for ovarian cancer: Laparoscopy or laparotomy? A prospective comparative study. Gynecol Oncol. 1999;72:411–417
  33. Nicoletto MO, Tumolo S, Salvagno L, et al.  Surgical second look in ovarian cancer: A randomized study in patients with laparoscopic complete remission. J Clin Oncol. 1997;15:994–999
  34. Consensus Development Panel on Ovarian Cancer NIH. NIH consensus conference: Ovarian cancer screening, treatment, and follow-up. JAMA. 1995;273:491–497
  35. Ozols RF, Bundy BN, Fowler J, et al.  Randomized phase III study of cisplatin/placitaxel vs. carboplatin/placitaxel in optimally debulked stage III epithelial ovarian cancer: A GOG trial (GOG 158). Proc Am Soc Clin Oncol. 1999;18:357a; (abstr)
  36. Griffiths CT: Surgical resection of tumor bulk in primary treatment of ovarian carcinoma. JNCI Morogr 42:101-104, 1075.
  37. Hoskins WJ, McGuire WP, Brady MF, et al.  The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–980
  38. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol. 1998;69:103–108
  39. Berek JS, Hacker NF, Lagasse LD, et al.  Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983;61:189–193
  40. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: Nonresponders to first-line therapy. Gynecol Oncol. 1989;33:1–5
  41. Kuhn W, Schmalfeldt D, Pache L, et al.  Disease-adapted relapse therapy for ovarian cancer: Results of a prospective study. Int J Oncol. 1998;13:57–63
  42. Gronlund B, Hogdall C, Hansen H, et al.  Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol. 2001;83:128–134
  43. Gore ME, Fryatt I, Wiltshaw E, et al.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–211
  44. Rose PG, Fusco N, Fluellen L, et al.  Second-line therapy with paclitaxel carboplatin for recurrent disease following first line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998;16:1494–1497
  45. Salmon E, Almeida Z, Mirhashemi R. Management of recurrent ovarian cancer: Evidenced-based decisions. Curr Opin Oncol. 2002;14:519–527

PII: S0093-7754(03)00100-3

Seminars in Oncology
Volume 30, Issue 3 , Pages 401-412 , June 2003

Article Tools

* Image Usage & Resolution